Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02069990
Recruitment Status : Completed
First Posted : February 24, 2014
Last Update Posted : February 24, 2014
Sponsor:
Collaborator:
Pharma Patent Kft.
Information provided by (Responsible Party):
Istvan Takacs, Semmelweis University

Brief Summary:

Circa-annual variations in 25-hydroxyvitamin D [25(OH)D] levels have been well established, and there also seems to be an effect of season on bone turnover and bone mass. been shown that bone turnover follows a circa-annual rhythm. On the basis of human clinical results, it was suggested that adipose tissue functions as a vitamin D buffering system that to a certain extent prevents uncontrolled synthesis of 25(OH)D in the liver. Directly related to this issue is the question of how much vitamin D is needed to ensure target serum 25-hydroxyvitamin D [25(OH)D] concentrations. According to the recommended dietary allowances, persons should achieve "levels of intake of essential nutrients considered to be adequate to meet the known nutritional needs of practically all healthy persons" Moreover it is important to note that the significant percentage of the population is temporarily of continuously deficient in vitamin D. In the similar condition of vitamin D deficiency, the aetiology is very different since only as almost exclusively as a consequence of a primary disease in children it is manifested: hypovitaminosis D is highly prevalent among children on renal substitution therapy, regardless of the type of therapy used and the stage of renal failure.

The rationale providing high dose strengths of vitamin D based on an assumption of better compliance especially in adult with senior age patients; also a potential for faster resolution of vitamin D deficiency, since utilization of cholecalciferol is higher when patients had low levels of 25(OH)D, and vice versa, there is a plateau phase when close to normal range (Vieth 2001).

According to clinical data, a doses equivalent of daily 1000 IU, (7000 IU per week, or 30000 IU per month) is considered as a minimal effective dose to treat vitamin D deficiency. The treatment of vitamin D with a duration of 30 days may result and increase of 6-12.5 nmol/L. With the deficiency criteria considered as <20 ng/ml, the vitamin supplementation is indicative, the treatment dosages should be adjusted to the increase planned to achieve the mid-normal range.

As the base of calculations, the doses of 40 IU results in an increase of 0.4 ng/ml in a period of 60 days. Accordingly 1000 IU in a period of 2-5 month resulted in an increase of approx 10 ng/ml. The risk of overdose in relatively low, since the absorption and the metabolic path is well controlled: automatic mechanisms downregulation at normal ranges.

In this study the there are three groups in the similar daily dose equivalent of 1000 IU/day. The absorption of daily , weekly and monthly dosing should have a buffered effect due to the body adipose tissues, balancing the daily 1,25(OH)D levels, and moreover to provide a biological reservoir. The three doses are considered as comparable in efficacy and safety.

The fourth group is intended to utilize the expanded dose range of 4286 IU/ day, using the 30.000 IU tablets on a weekly dosing schedule. This group is to demonstrate the efficacy of higher doses to normalize the vitamin D levels, within a reasonable timeframe of 60-90 days.


Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Drug: Cholecalciferol Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : March 2013
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 30000 IU cholecalcipherol once a week
30000 IU cholecalcipherol once a week oral
Drug: Cholecalciferol
Experimental: 7000 IU cholecalcipherol once a week
7000 IU cholecalcipherol once a week oral
Drug: Cholecalciferol
Experimental: 30000IU cholecalcipherol once a month
30000IU cholecalcipherol once a month oral
Drug: Cholecalciferol
Active Comparator: 1000 IU cholecalciferol once a day
1000 IU cholecalciferol once a day
Drug: Cholecalciferol



Primary Outcome Measures :
  1. Serum 25-OH-Vitamin-D level [ Time Frame: 12 weeks ]

    Based on the changes in 25(OH)D versus to baseline, in each group, and compared to the group of 1000 IU daily dosage applied.

    1000 IU /day vs. 7000 IU/ week, eqv. 1000 IU/ day vs 30000 IU/ month egv. 1000 IU /day vs 30000 IU/week: superiority



Secondary Outcome Measures :
  1. number of adverse events [ Time Frame: 12 weeks ]
    Frequency of adverse events for each group compared to group "A" ( as standard 1000 IU/day therapy). Evaluation of adverse event includes patient reported symptoms and safety laboratory (seCa, seP, se creatinine, urinary Ca) abnormalities.

  2. Serum PTH [ Time Frame: 12 weeks ]
  3. Urinary calcium [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subject are included as 18 years or older ( adults) with the following specific criteria:

  • 25(OH)D level < 50 nmol/L (20 ng/ml)
  • female subjects either postmenopausal status or under proper (continuous) contraception during the course of the study are allowed to be enrolled
  • Subject informed willing to participate and ICF signed and dated properly

Exclusion Criteria:

  • hypercalcaemia/ se Ca levels out of 2.20-2.60 mmol/L range
  • symptoms or lab results of elevated se Ca during the last year
  • hypercalciuria within the last two years
  • renal stones formation in anamnesis
  • sever kidney disease ( CKD 3 or higher grade)
  • chronic or serious illness that may result in malabsorption, the metabolisms of vitamin D or bones
  • severe grade of metabolic diseases, bone disorders, excluded the primary age related osteoporosis,
  • obesity ( BMI>35)
  • diseases that resulted in changed absorption of calcium
  • CHF or angina pectoris,
  • recent (<3 month) surgical traumatic treatment
  • alcohol or drug abuse,
  • Vitamin D therapy or food supplements applied with the last 2 months, (at 1000 IU or above)
  • planned travel (more than 5 days-long to a region of high natural UVB exposition)
  • regular ( >2 per month) artificial UVB exposition (solarium)
  • permanent use of non-permitted concomitant medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02069990


Locations
Layout table for location information
Hungary
Semmelweis University 1st Dept. of Int. Med-
Budapest, Hungary, 1083
Ambulatory Dept of Józsefváros Health Services
Budapest, Hungary, 1084
Sponsors and Collaborators
Semmelweis University
Pharma Patent Kft.
Investigators
Layout table for investigator information
Principal Investigator: Peter Lakatos, professor Semmelweis University
Layout table for additonal information
Responsible Party: Istvan Takacs, university docent, Semmelweis University
ClinicalTrials.gov Identifier: NCT02069990    
Other Study ID Numbers: PAT12-730DS
First Posted: February 24, 2014    Key Record Dates
Last Update Posted: February 24, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Cholecalciferol
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents